During the past decade, Chvng - Unidade I conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chvng - Unidade I" #1 sponsor was "Janssen Research & Development, LLC" with 3 trials, followed by "Associacao de Investigacao de Cuidados de Suporte em Oncologia" with 2 trials sponsored, "Abbott Medical Devices" with 1 trials sponsored, "Daiichi Sankyo, Inc." with 1 trials sponsored and "EMD Serono Research & Development Institute, Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chvng - Unidade I" #1 collaborator was "Centro Hospitalar de Vila Nova de Gaia/Espinho" with 2 trials as a collaborator, "University Institute of Maia" with 2 trials as a collaborator, "Aveiro University" with 1 trials as a collaborator, "GORTEC (Head and Neck Oncology and Radiotherapy Group)" with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Chvng - Unidade I" are "Breast Cancer" (1 trials), "Colitis, Ulcerative" (1 trials), "Crohn Disease" (1 trials), "Crohn's Disease" (1 trials) and "EGFR Exon 19 Deletion" (1 trials). Many other conditions were trialed in "Chvng - Unidade I" in a lesser frequency.

Most popular intervention types in "Chvng - Unidade I" are "Drug" (5 trials), "Biological" (2 trials), "Other" (2 trials), "Device" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Golimumab" (2 trials), "Guselkumab" (2 trials), "JNJ-78934804" (2 trials) and "Cisplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Chvng - Unidade I" are 7 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Chvng - Unidade I". undefined are not yet recruiting, 5 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Chvng - Unidade I, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Chvng - Unidade I, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".